HC Wainwright restated their neutral rating on shares of Kyverna Therapeutics (NASDAQ:KYTX – Free Report) in a research report released on Tuesday, Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright also issued estimates for Kyverna Therapeutics’ FY2024 earnings at ($2.56) EPS.
Kyverna Therapeutics Trading Down 0.2 %
NASDAQ KYTX opened at $10.48 on Tuesday. The firm has a 50 day moving average price of $11.14. Kyverna Therapeutics has a 1-year low of $6.75 and a 1-year high of $35.06.
Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.28). During the same quarter in the previous year, the business earned ($12.10) earnings per share. On average, research analysts predict that Kyverna Therapeutics will post -3.34 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Kyverna Therapeutics
About Kyverna Therapeutics
Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
Featured Articles
- Five stocks we like better than Kyverna Therapeutics
- When to Sell a Stock for Profit or Loss
- This Cybersecurity Stock Gains Analysts’ Favor for Strong Growth
- 3 Warren Buffett Stocks to Buy Now
- Parabolic Rise of This Stock Shows No Signs of Slowing
- How to Use Stock Screeners to Find Stocks
- Risk Tolerance vs. Risk Appetite: Key Differences
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.